Trial Profile
A randomised, multicentre, open label trial in patients with relapse or refractory acute myeloid leukemia to evaluate the antileukemic potential of the pharmaco-modulation of sequential high-dose cytarabine by fludarabine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2015
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 30 Nov 2015 New trial record